The project could eventually add more than 400 manufacturing jobs and over 1,500 construction jobs during site development.

HHS Secretary Robert F. Kennedy Jr. and biopharmas will negotiate drug prices individually. Kennedy could "propose a rulemaking plan to impose MFN pricing" if no “significant” progress has been made.

Researchers use generative AI to design synthetic enhancers that can effectively control gene expression in healthy mammalian ...

Ansa is accepting orders for synthetic DNA constructs ranging from 7.5 kb up to 50 kb for various applications.

Discovery of innate immune receptor "brake" Siglec-E offers a novel therapeutic target to prevent organ transplant rejection ...

Astraveus' technology possesses the ability to simultaneously decrease manufacturing costs while increasing process ...

Lipid receptor SR-B1 identified as a potential immunotherapy target to boost NK cell antitumor response in advanced ovarian ...

The virus likely reached humans not via bat migration but through the wildlife trade—contradicting hypotheses that it may ...

BMS pledges $40B over five years to boost U.S. R&D, tech innovation, and pharmaceutical manufacturing under CEO Christopher ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a ...

Researchers expect LICONN technology will be broadly useful to enable high-resolution tissue analysis in other organs and ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in ...